Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. (Q53592017)
Jump to navigation
Jump to search
scientific article published on 5 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. |
scientific article published on 5 March 2015 |
Statements
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. (English)
Jean-Paul Guastalla
Véronique Diéras
Hans Wildiers
Luc Y Dirix
Petri Bono
Sara A Hurvitz
Anthony Gonçalves
Gilles Romieu
Steven A Limentani
Guy Jerusalem
K C Lakshmaiah
Henri Roché
Pedro Sánchez-Rovira
Miguel Ángel Seguí Palmer
Ai Li
Yu-Nien Sun
Cheryl A Pickett
5 March 2015